Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery
The company’s comprehensive viral target atlas is designed to move development from reactive crisis response toward proactive, pre-identified genomic vulnerability mapping
Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced it has mapped CRISPR-addressable regions across 25 out of 25 viral families known to infect humans, creating a comprehensive atlas of viral genetic vulnerabilities that may support faster identification of antiviral target sites against known pathogens, emerging variants, and future outbreak threats.
Antiviral development has been reactive: a virus emerges, the world scrambles to characterize it, and countermeasure development begins under crisis conditions. Recent Ebola outbreaks illustrate both the success and the gap in today’s approach. For Zaire ebolavirus, there is an approved vaccine, demonstrating targeted intervention against a lethal virus can be clinically meaningful and globally crucial. But Bundibugyo virus, another ebolavirus, highlights the limitations of species- and strain-specific countermeasures.
